NASDAQ:GNPX Genprex Q3 2025 Earnings Report $2.70 +0.08 (+3.21%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Genprex EPS ResultsActual EPS-$110.00Consensus EPS -$275.00Beat/MissBeat by +$165.00One Year Ago EPSN/AGenprex Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGenprex Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsGenprex's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Genprex Earnings HeadlinesGenprex to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | prnewswire.comGenprex advances AAV diabetes gene therapy manufacturingAugust 18, 2026 | tipranks.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.October 8 at 1:00 AM | Paradigm Press (Ad)Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene TherapyAugust 18, 2026 | prnewswire.comLung cancer gene therapy takes first step toward AI biomarker selectionAugust 3, 2026 | msn.comGenprex shares rise after collaboration with Roche DiagnosticsAugust 3, 2026 | msn.comSee More Genprex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email. Email Address About GenprexGenprex (NASDAQ:GNPX), Inc. is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s technology is designed to deliver therapeutic genes into cells using a nonviral delivery system, with the goal of restoring tumor-suppressor activity or producing other disease-fighting effects. Genprex’s lead product candidate is REQORSA® Immunogene Therapy (quaratusugene ozeplasmid), an investigational gene therapy being developed primarily for non-small cell lung cancer. The company has evaluated REQORSA in combination with established cancer treatments, including targeted therapies and immunotherapies, and has also investigated its potential in other oncology applications. Genprex is headquartered in Austin, Texas. Its programs remain in clinical development and have not been approved for general commercial use. The company has also pursued gene-therapy research in diabetes, although its principal publicly identified development focus has been oncology.View Genprex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look Real Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
